What happened

BillionToOne, Inc. (NASDAQ: BLLN) rose 12.0% to $116.28 by 2:20 p.m. ET on September 22. The previous regular-session close was $103.86.

That quote implies an equity value of about $5.49 billion using 47.2 million Class A and Class B shares outstanding as of August 3. No clear material company-specific or broader catalyst appeared in the issuer releases, SEC filings, analyst-action pages, trading-halt sources or market reporting reviewed through that time.

The latest issuer release was a September 2 conference-participation notice. Recent Form 4 sales, a routine industry event and news around other diagnostics companies were reviewed, but none supplied a clear explanation for today's move. This is a bounded finding, and the price jump is not evidence that the business changed today.

Explain the financial terms

A Form 4 is the SEC report an officer, director or 10% owner files within two business days of buying or selling the company's stock.

How the business works

BillionToOne, Inc. (NASDAQ: BLLN) started with UNITY, a prenatal test launched in 2019. It added the Northstar oncology tests in 2023. Both franchises use the company's single-molecule next-generation sequencing platform and its patented Quantitative Counting Templates.

The technical idea is easier than the name. DNA fragments in blood are amplified before sequencing, which can introduce noise. BillionToOne, Inc. (NASDAQ: BLLN) adds synthetic control fragments, then uses software to count rare target molecules and correct for that noise. The goal is to find weak fetal or tumor signals from one blood draw.

UNITY estimates fetal risk for inherited conditions without requiring a paternal sample. Northstar Select looks for mutations that can guide cancer therapy, while Northstar Response measures changes in tumor burden. Clinicians order the tests, the company's labs process them, and BillionToOne, Inc. (NASDAQ: BLLN) bills insurers, government programs or patients.

That last step matters as much as the science. Third-party payers generated more than 90% of 2025 revenue. A test can be clinically useful and still produce weak economics if coverage is narrow, claims are denied or collections arrive slowly.

The investment case

The operating evidence is strong. Second-quarter revenue rose 64% to $109.4 million. Test volume grew 35% to 196,000, and overall average selling price rose 21%. Gross margin improved five percentage points to 70%, while operating income reached $5.5 million.

Growth also came from both franchises. Prenatal revenue rose 55% to $94.2 million, and oncology revenue rose 176% to $13.7 million. Oncology is still small, but it gives BillionToOne, Inc. (NASDAQ: BLLN) a second engine beyond prenatal testing and a way to reuse the same core counting platform.

Management reiterated full-year revenue guidance of $450 million to $465 million. At the midpoint, today's equity value equals about 12.0 times expected revenue. That is the decisive number: investors are already paying for durable adoption, strong reimbursement and much more margin expansion, not merely another year of fast test growth.

The balance sheet supports the case. BillionToOne, Inc. (NASDAQ: BLLN) held $548.6 million of cash against $91.0 million of debt at June 30, and generated $24.6 million of operating cash in the first half. Near-term financing risk is low if collections and profitability hold.

Explain the financial terms

A balance sheet shows a company's assets, debts and owners' equity at a point in time.

A fiscal quarter is a three-month period in the company's reporting year.

A profit margin expresses the specified profit measure as a share of sales.

Guidance is management's forecast, not a completed result.

The market and competition

BillionToOne, Inc. (NASDAQ: BLLN) estimated that its current products address more than $20 billion of annual U.S. opportunity and that its pipeline could expand that above $100 billion. Those are issuer estimates, not audited market forecasts. Half of the larger figure comes from early cancer detection, where the company had not begun specific product development or commercial sales when it filed its prospectus.

The real current market is still large. The company cited about 3.7 million U.S. births in 2023, while its oncology products target therapy selection and treatment monitoring across solid tumors. Market size does not guarantee share, reimbursement or repeat ordering.

Natera, Inc. (NASDAQ: NTRA) competes in prenatal testing and oncology. Guardant Health, Inc. (NASDAQ: GH) and Tempus AI, Inc. (NASDAQ: TEM) compete in liquid biopsy and therapy selection. BillionToOne, Inc. (NASDAQ: BLLN) argues that single-molecule quantification improves sensitivity, but competitors have broader commercial networks, established payer relationships or larger product portfolios.

The risks

Valuation is the first risk. A 12.0 times revenue multiple leaves little room for a reimbursement setback or a normal slowdown. Second-quarter operating margin was only 5%, so the stock still needs growth to convert into much more operating profit.

Cash conversion also deserves attention. Accounts receivable increased to $74.9 million at June 30 from $41.6 million at year-end. Revenue was expanding quickly too, but receivables grew about 80%. If payer denials or payment delays rise, reported revenue and cash generation can separate.

Coverage is uneven. The filing says some UNITY add-ons have limited insurance coverage, Northstar Select has narrower commercial coverage than Medicare, and Northstar Response lacks broad Medicare or commercial coverage. Pricing gains can reverse if payers or medical guidelines change.

Intellectual-property and competition risks are concrete. Illumina, Inc. (NASDAQ: ILMN) sued in May, alleging that UNITY infringes three patents. BillionToOne, Inc. (NASDAQ: BLLN) says the claims lack merit, but litigation can consume cash or disrupt a core product even when management expects to prevail.

Explain the financial terms

A fiscal quarter is a three-month period in the company's reporting year.

A profit margin expresses the specified profit measure as a share of sales.

What's next

The next quarterly report is the cleanest test. Watch whether test volume, average selling price and gross margin stay strong enough to support the $450 million to $465 million revenue guide while operating cash remains positive.

Product evidence matters too. The expanded UNITY fetal-risk panel launched in August, and Northstar Origin launched in September. Investors should look for adoption and reimbursement evidence, not launch announcements alone. Progress toward broader Northstar Response coverage would be especially meaningful.

Today's rise makes the story more expensive, not more proven. The investment case strengthens if differentiated tests keep winning orders while collections and margins scale. It weakens if payer friction, competition or litigation breaks that operating leverage.

Explain the financial terms

A profit margin expresses the specified profit measure as a share of sales.

Sources checked automatically Sep 22, 2026 · Human review: none
Thesis impactBLLN: no published thesis yet.

The evidence behind the claim

Current-price screen plus a dated review of issuer releases, SEC filings, Nasdaq news and halt sources, analyst actions, market reporting, peer moves and relevant diagnostics-sector developments. The catalyst finding is bounded by the sources and time checked.

Download evidence and sources (CSV)

ClaimObserved evidenceDate / source
Q2 growth, profitability and 2026 guidanceRevenue rose 64%, gross margin reached 70%, operating income was positive and management reiterated $450 million to $465 million of 2026 revenue.August 5, 2026
Second-quarter results ↗
Reimbursement and collection riskThird-party payers generated more than 90% of 2025 revenue, while coverage remains uneven across several UNITY and Northstar uses.March 11, 2026
2025 Form 10-K ↗
Market-scale limitationThe issuer estimated more than $20 billion for current products and more than $100 billion with pipeline products, but half of the larger figure depends on early detection where specific product development and commercial sales had not begun.November 6, 2025
IPO prospectus ↗